Serum angiotensin-converting enzyme (ACE) activity is elevated in an active stage of sarcoidosis (Lieberman 1975 ). Although the mechanisms by which the enzyme activity is increased are not completely elucidated, corticosteroid therapy decreased ACE activity coincidentally with clinical and radiographic improvement (Lieberman et al. 1979) . Recently, an orally active converting-enzyme inhibitor, captopril, was synthesized (Ondetti et al. 1977 ) and was shown successfully to lower blood pressure in hypertensive patients (Furguson et al. 1977; Mizuno et al. 1981a ). However, the literature dealing with the effect of captopril on ACE activity in sarcoidosis has been scarce. In the present study, we examined acute effects of this inhibitor on ACE activity as well as on plasma renin activity (PRA), plasma concentration of aldosterone (PAC) and blood pressure in patients in an active stage of sarcoidosis.
Three patients with sarcoidosis (2 females and 1 male, aged 21-54 years) were kept fasted and recumbent overnight. After drawing 0 min blood samples, captopril (25 mg) was given orally. Blood was drawn at 30, 60. 90 and 120 min after the administration for determinations of serum ACE activity, PRA and PAC. Blood pressure was also measured before and after captopril. ACE activity was measured by the spectrophotometric method using hippuryl-histidyl-leucine as substrate (Mizuno et al. 1981b) . One unit of the enzyme activity was defined in terms of one nmole hippuric acid formed/ml/min at 37°C. In our laboratory, normal values of ACE activity were 18.0 to 25.0 units/ml. Radioimmunoassay methods were used for determinations of PRA (Fukuchi et al. 1971a ) and PAC (Fukuchi et al. 1971b ). Results were presented as means+s.E. Statistical analysis was performed with Student's paired sample t-test. Table 1 depicts our principal data. Serum ACE activity was rapidly and remarkably decreased from a control of 42.4±4.8 to 12.1±1.9 units (p<0.02) 30 min after the administration. The activity remained at low levels of 11.6±2.8 units (p<0.02) even 120 min after captopril. PAC and mean arterial pressure (MAP) were slightly but significantly lowered. PRA was increased in a patient (No. 1), but the overall response was not significant (Table 1) .
Although it is uncertain whether rtiptopril suppresses production of convertingenzyme, which might be done in sarcoid lesion, the present results clearly demonstrated that captopril inhibits serum ACE activity with subsequent decrease in PAC and reduction of blood pressure, indicating that captopril may offer an effective therapeutic approach to the treatment of active stage of sarcoidosis.
Thus, effect of long-term administration of captopril on serum ACE level as well as on clinical symptoms must be evaluated in more detail in sarcoidosis. 
